Kailo Pharma is an Israeli medical startup commercializing University of Haifa research aimed at directly treating PTSD. Its lead approach targets a newly identified brain mechanism tied to pathological amplification of traumatic memories, with the goal of weakening trauma intensity without erasing normal memory. The company is developing a peptide-based therapy intended for nasal delivery to reach the central nervous system.